The Food and Drug Administration (FDA) has approved Ingrezza (valbenazine) capsules, the first drug to treat the neurological disorder tardive dyskinesia. Tardive dyskinesia is a neurological disorder characterized by repetitive involuntary movements, usually of the jaw, lips and tongue, such as grimacing, sticking out the tongue and smacking the lips. Some people affected by the condition also experience involuntary movement of the extremities or difficulty breathing. Not only is the condition disabling, it can further stigmatize patients with mental illness, as it is caused by antipsychotic medications, especially older drugs, taken for long periods of time to treat chronic conditions ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.